ImClone begins Phase II in NSCLC

IMCL began a Phase II trial of its IMC-C225 anti- EGFR monoclonal antibody in combination with carboplatin and paclitaxel to treat non-small cell lung carcinoma in newly diagnosed patients. IMC-C225, ...